Detalhe da pesquisa
1.
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
N Engl J Med
; 384(3): 238-251, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33332778
2.
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
N Engl J Med
; 385(13): 1184-1195, 2021 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34347950
3.
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
N Engl J Med
; 385(23): e81, 2021 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34587383
4.
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
J Infect Dis
; 227(1): 23-34, 2022 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35895508
5.
Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.
Clin Infect Dis
; 75(1): e380-e388, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35219277
6.
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
JAMA
; 327(5): 432-441, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35029629
7.
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
JAMA Netw Open
; 5(8): e2225411, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35969402
8.
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
Int J Infect Dis
; 122: 585-592, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35788416
9.
Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
medRxiv
; 2021 Sep 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34159343
10.
Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention.
medRxiv
; 2021 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34159344